Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Latvia

Marie Skłodowska-Curie Action · Running

BioMIX Biomimetic MXene Nanoplatforms for Targeted Combination Therapy of Triple-Negative Breast Cancer

Coordinator
Latvijas Universitate, Latvia
Runs
1 November 2026 to 31 October 2030
Status
Running
EU funding
€1.1m
Total cost
—
Partners
13 organisations in 12 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101344052

What the project is doing

In the project's own words, from its summary on CORDIS.

Triple-Negative Breast Cancer (TNBC) remains one of the most challenging subtypes of oncology due to its high metastatic potential, lack of targeted receptors, and rapid development of drug resistance. The BioMIX project proposes a disruptive solution: a ""stealth"" biomimetic nanoplatform designed to bypass the immune system and deliver a potent combination of chemotherapy, gene therapy, and sonodynamic therapy (SDT) directly to the tumor site.

The core of the BioMIX technology is a two-dimensional Ti3C2 MXene nanosheet, which serves as a structural scaffold and a high-efficiency sonosensitizer. This core is functionalized with a pH-responsive polydopamine shell to entrap Doxorubicin and a cationic layer to complex anti-MDR1 siRNA. To achieve superior targeting, the construct is ""camouflaged"" with a hybrid membrane fused from TNBC cells and macrophages, further enhanced with iRGD peptides for deep-tissue penetration.

Upon reaching the tumor, low-intensity ultrasound is applied to trigger localized hyperthermia and reactive oxygen species (ROS) generation, causing controlled drug release and inducing targeted cancer cell apoptosis. As an MSCA Staff Exchange action, BioMIX is built on a highly interdisciplinary consortium of 13 international partners across the academic and industrial sectors. The project is structured to facilitate more than 200 person-months of knowledge transfer, conveying critical expertise in 2D materials science, microfluidic manufacturing, and preclinical oncology research.

By integrating ""Tumor-on-a-Chip"" validation and in vivo efficacy studies, BioMIX aims to establish a clinically translatable framework for targeted nanomedicine while reducing the systemic side effects (such as cardiotoxicity) of conventional chemotherapy. The project’s outcomes will strengthen European leadership in nanobiotechnology and provide a scalable framework for the next generation of biomimetic therapeutic vehicles aligned with Europe’s Beating Cancer Plan.""

Topics

Who is involved

OrganisationCityCountryRole
Latvijas UniversitateRigaLatviaCoordinator
Khalifa University of Science and TechnologyAbu DhabiAEAssociatedpartner
YoursciencebeBruxelles / BrusselBelgiumParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Universita Degli Studi Di PadovaPadovaItalyParticipant
Mb SensografaVilniusLithuaniaParticipant
Auckland University of TechnologyAucklandNew ZealandAssociatedpartner
Uniwersytet Im. Adama Mickiewicza WpoznaniuPoznanPolandParticipant
Biofabics LdaPortoPortugalParticipant
Ankara UniversitesiTandogan AnkaraTürkiyeParticipant
Csd Health CareKyivUkraineParticipant
Materials Research CenterKievUkraineParticipant
The University of LiverpoolLiverpoolUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI